Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scimed v. ACS

This article was originally published in The Gray Sheet

Executive Summary

Lilly subsidiary Advanced Cardiovascular Systems' motion to stay litigation filed by Scimed is granted by U.S. District Court for the Northern District of California. Litigation proceedings in the case are postponed indefinitely, according to ACS. Scimed had filed suit May 31, alleging that ACS' Flowtrack 40 and Rx Elipse percutaneous transluminal coronary angioplasty catheters infringe two of its patents ("The Gray Sheet" June 6, In Brief). ACS' motion to stay argued that a settlement agreement reached between the two companies in August 1991 applied to this case. The settlement, according to ACS, included an arbitration provision and a covenant not to sue

You may also be interested in...



Biogen Value-Based Contract Links Patient-Reported Outcomes To MS Drug Reimbursement

Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.

Outcomes-Based Contracts May Rely More On Patient-Reported Results

As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.

Industry Advocacy Group Goes Global After Device Tax Repeal

After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.

UsernamePublicRestriction

Register

MT002690

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel